Clinical Trial

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) for patients with hepatocellular carcinoma and microvascular invasion (MVI) after hepatectomy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-17.
Trial Details
NCT Number NCT06089369
Lead Sponsor Tongji Hospital
Conditions Hepatocellular Carcinoma
Enrollment 360 participants
Start Date 2024-06-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-04-30